Rural Health
Resources by Topic: Pharmacy and prescription drugs
Inequity, Workload, and External Factors: A Descriptive Study on High-Intensity Statin Prescriptions for Patients with Clinical Cardiovascular Disease and at High Risk for Cardiovascular Disease
Examines adherence to guidelines related to statin prescriptions to treat atherosclerotic cardiovascular disease (ASCVD). Utilizes medical chart data from 20,923 ASCVD patients according to statin prescribing rates and patient demographics, including rural versus urban residence.
Author(s): Liberty Nguyen, Ethlyn Voorhies, Christy Jesme, et al.
Citation: BMC Cardiovascular Disorders, 25, 718
Date: 10/2025
view details
Examines adherence to guidelines related to statin prescriptions to treat atherosclerotic cardiovascular disease (ASCVD). Utilizes medical chart data from 20,923 ASCVD patients according to statin prescribing rates and patient demographics, including rural versus urban residence.
Author(s): Liberty Nguyen, Ethlyn Voorhies, Christy Jesme, et al.
Citation: BMC Cardiovascular Disorders, 25, 718
Date: 10/2025
view details
Estimating Emergency Department Utilization of Select Drugs during Extreme Heat Events
Examines excess emergency department (ED) visits and drug utilization surges for heat-related illness. Utilizes medical claims data to analyze heatwave related illnesses and provides modeling that predicts associated ED visits and drug utilization surges. Includes a county-level U.S. map showing days of extreme heat each year and discusses the impact on rural areas.
Author(s): Daniel McGeeney, Shruti Rathnavel, Emily McAden, Clifton Dassuncao, Aylin Sertkaya
Date: 09/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Examines excess emergency department (ED) visits and drug utilization surges for heat-related illness. Utilizes medical claims data to analyze heatwave related illnesses and provides modeling that predicts associated ED visits and drug utilization surges. Includes a county-level U.S. map showing days of extreme heat each year and discusses the impact on rural areas.
Author(s): Daniel McGeeney, Shruti Rathnavel, Emily McAden, Clifton Dassuncao, Aylin Sertkaya
Date: 09/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Diabetes in Pennsylvania: Prevention and Maintenance Programs
Present data and describes government and non-government programs working to help people prevent and manage diabetes in Pennsylvania. Includes information about possible new treatments and summaries of other new research on diabetes including the effects of social determinants of health. Mentions special needs of rural and underserved populations.
Author(s): Allison Kobzowicz, Lydia K. Ring, Wendy L. Baker
Date: 09/2025
Sponsoring organization: Joint State Government Commission, General Assembly of the Commonwealth of Pennsylvania
view details
Present data and describes government and non-government programs working to help people prevent and manage diabetes in Pennsylvania. Includes information about possible new treatments and summaries of other new research on diabetes including the effects of social determinants of health. Mentions special needs of rural and underserved populations.
Author(s): Allison Kobzowicz, Lydia K. Ring, Wendy L. Baker
Date: 09/2025
Sponsoring organization: Joint State Government Commission, General Assembly of the Commonwealth of Pennsylvania
view details
Rural Providers' Attitudes Toward Integrating Harm Reduction Strategies and PrEP Prescribing into Rural Primary Care Settings in the US. Southeast and Midwest
Examines the perceptions of providers working in rural primary care settings toward buprenorphine, methadone, comprehensive harm reduction, and PrEP prescriptions. Analyzes 409 providers treating either a person with opioid use disorder or a person with HIV and provides data breakdowns on PrEP prescriptions, medications for opioid use disorder (MOUD), and perceptions toward harm reduction integration.
Author(s): Phillip L. Marotta, Miryam Biaid, Robert Heimer, et al.
Citation: Addiction Science & Clinical Practice, 20, 73
Date: 09/2025
view details
Examines the perceptions of providers working in rural primary care settings toward buprenorphine, methadone, comprehensive harm reduction, and PrEP prescriptions. Analyzes 409 providers treating either a person with opioid use disorder or a person with HIV and provides data breakdowns on PrEP prescriptions, medications for opioid use disorder (MOUD), and perceptions toward harm reduction integration.
Author(s): Phillip L. Marotta, Miryam Biaid, Robert Heimer, et al.
Citation: Addiction Science & Clinical Practice, 20, 73
Date: 09/2025
view details
Medications for Opioid Use Disorder among Adults Who Had an Opioid Use Disorder
Offers National Survey on Drug Use and Health (NSDUH) data on adults receiving medications for opioid use disorder (MOUD) between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
Offers National Survey on Drug Use and Health (NSDUH) data on adults receiving medications for opioid use disorder (MOUD) between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
The 340B Drug Discount Program: Litigation Topics and Trends
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Growth in the 340B Drug Pricing Program
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021
Analyzes fill rates for GLP1RA and SGLT2i glucose-lowering drugs among people with type 2 diabetes by level of rurality and other demographics, utilizing 2012-2021 OptumLabs Data Warehouse claims data. Discusses how geographic differences in prescribing may influence cardiovascular and kidney disease outcomes among people with type 2 diabetes.
Author(s): Kyle Steiger, Kavya Sindhu Swarna, Jeph Herrin, Rozalina G. McCoy
Citation: Journal of General Internal Medicine, 41, 126-133
Date: 08/2025
view details
Analyzes fill rates for GLP1RA and SGLT2i glucose-lowering drugs among people with type 2 diabetes by level of rurality and other demographics, utilizing 2012-2021 OptumLabs Data Warehouse claims data. Discusses how geographic differences in prescribing may influence cardiovascular and kidney disease outcomes among people with type 2 diabetes.
Author(s): Kyle Steiger, Kavya Sindhu Swarna, Jeph Herrin, Rozalina G. McCoy
Citation: Journal of General Internal Medicine, 41, 126-133
Date: 08/2025
view details
Pharmacy Barriers to Receiving Buprenorphine among Patients Undergoing Telemedicine Addiction Treatment
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Rural Beneficiary Access to Medicare Advantage-Part D Plans
Policy brief updating RUPRI's analysis of Medicare Advantage-Part D plans (MA-PDs) including enhanced benefit plan availability and differences in characteristics across metropolitan, micropolitan, and noncore areas. Features statistics including number of MA-PDs and stand-alone prescription drug plans (PDPs), average monthly premium costs, and availability in metropolitan, micropolitan, and noncore areas from 2008-2023.
Author(s): Edmer Lazaro, Dan M. Shane, Fred Ullrich, Keith Mueller
Date: 08/2025
Sponsoring organization: RUPRI Center for Rural Health Policy Analysis
view details
Policy brief updating RUPRI's analysis of Medicare Advantage-Part D plans (MA-PDs) including enhanced benefit plan availability and differences in characteristics across metropolitan, micropolitan, and noncore areas. Features statistics including number of MA-PDs and stand-alone prescription drug plans (PDPs), average monthly premium costs, and availability in metropolitan, micropolitan, and noncore areas from 2008-2023.
Author(s): Edmer Lazaro, Dan M. Shane, Fred Ullrich, Keith Mueller
Date: 08/2025
Sponsoring organization: RUPRI Center for Rural Health Policy Analysis
view details